• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COX 2 inhibitors, traditional NSAIDs, and the heart.

作者信息

Jüni Peter, Reichenbach Stephan, Egger Matthias

出版信息

BMJ. 2005 Jun 11;330(7504):1342-3. doi: 10.1136/bmj.330.7504.1342.

DOI:10.1136/bmj.330.7504.1342
PMID:15947376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC558270/
Abstract
摘要

相似文献

1
COX 2 inhibitors, traditional NSAIDs, and the heart.环氧化酶-2抑制剂、传统非甾体抗炎药与心脏
BMJ. 2005 Jun 11;330(7504):1342-3. doi: 10.1136/bmj.330.7504.1342.
2
[Selective COX-2 inhibitors--side effects in relation to non-specific non-steroidal anti-inflammatory drugs].[选择性环氧化酶-2抑制剂——与非特异性非甾体抗炎药相关的副作用]
Ugeskr Laeger. 2004 Dec 6;166(50):4581-4.
3
COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.环氧化酶-2（COX-2）抑制剂：比传统非甾体抗炎药更好吗？万络和西乐葆的风险可能并不亚于非甾体抗炎药。
Health News. 2002 Aug;8(8):5.
4
Adverse Drug Events Involving COX-2 Inhibitors.涉及COX-2抑制剂的药物不良事件。
Ann Pharmacother. 2003 Sep;37(9):1203-13. doi: 10.1345/aph.1A212.
5
New NSAIDs and gastroduodenal damage.新型非甾体抗炎药与胃十二指肠损伤
Ital J Gastroenterol. 1996 Dec;28 Suppl 4:28-9.
6
Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option.COX-2抑制剂和非甾体抗炎药引起胃肠道不良反应的风险：COX-2抑制剂曾被认为是一种安全的选择。
BMJ. 2005 Dec 17;331(7530):1474. doi: 10.1136/bmj.331.7530.1474-b.
7
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.选择性环氧化酶-2（COX-2）抑制剂是否优于传统非甾体抗炎药（NSAIDs）？CLASS试验和VIGOR试验均支持COX-2假说。
BMJ. 2002 Jul 20;325(7356):161; author reply 161.
8
Standard NSAIDs vs. COX-2 inhibitors.标准非甾体抗炎药与环氧化酶-2抑制剂对比
Johns Hopkins Med Lett Health After 50. 2002 Jan;13(11):3.
9
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.选择性环氧化酶-2抑制剂是否优于传统非甾体抗炎药？法玛西亚公司对一篇社论的回应。
BMJ. 2002 Jul 20;325(7356):161; author reply 161.
10
By the way, doctor. I'm confused. I've read your articles about heart disease being caused by inflammation. If the COX-2 drugs are anti-inflammatory, why do they seem to make heart disease worse, not better?顺便问一下，医生。我很困惑。我读了你关于心脏病是由炎症引起的文章。如果COX - 2药物是抗炎的，为什么它们似乎会使心脏病恶化，而不是好转呢？
Harv Health Lett. 2005 May;30(7):8.

引用本文的文献

1
Research on electroacupuncture parameters for knee osteoarthritis based on data mining.基于数据挖掘的膝骨关节炎电针参数研究。
Eur J Med Res. 2022 Aug 31;27(1):162. doi: 10.1186/s40001-022-00795-9.
2
Investigation of Active Anti-Inflammatory Constituents of Essential Oil from (Sieb. et Zucc.) Wood in LPS-Stimulated RBL-2H3 Cells.研究辛夷挥发油中活性抗炎成分对脂多糖刺激的 RBL-2H3 细胞的作用。
Biomolecules. 2021 May 31;11(6):817. doi: 10.3390/biom11060817.
3
Design, formulation and evaluation of Hochst and Linn based gel for its analgesic and anti-inflammatory activities.基于Hochst和Linn的凝胶的设计、配方及其镇痛和抗炎活性评估。
Heliyon. 2020 Sep 14;6(9):e04894. doi: 10.1016/j.heliyon.2020.e04894. eCollection 2020 Sep.
4
The effectiveness and safety of acupuncture for knee osteoarthritis: An overview of systematic reviews.针灸治疗膝骨关节炎的有效性和安全性：系统评价概述
Medicine (Baltimore). 2019 Jul;98(28):e16301. doi: 10.1097/MD.0000000000016301.
5
Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth.使用托芬那酸靶向特异性蛋白1转录因子和生存素以抑制尤因肉瘤细胞生长。
Invest New Drugs. 2017 Apr;35(2):158-165. doi: 10.1007/s10637-016-0417-9. Epub 2016 Dec 26.
6
Novel anti-inflammatory activity of epoxyazadiradione against macrophage migration inhibitory factor: inhibition of tautomerase and proinflammatory activities of macrophage migration inhibitory factor.环氧补骨脂素对巨噬细胞移动抑制因子的抗炎新活性：抑制巨噬细胞移动抑制因子的互变异构酶和促炎活性。
J Biol Chem. 2012 Jul 13;287(29):24844-61. doi: 10.1074/jbc.M112.341321. Epub 2012 May 29.
7
Why we need easy access to all data from all clinical trials and how to accomplish it.为什么我们需要方便地获取所有临床试验的数据，以及如何实现这一目标。
Trials. 2011 Nov 23;12:249. doi: 10.1186/1745-6215-12-249.
8
Serotonin Receptor 2A/C Is Involved in Electroacupuncture Inhibition of Pain in an Osteoarthritis Rat Model.5-羟色胺受体 2A/C 参与电针对骨关节炎大鼠模型疼痛的抑制作用。
Evid Based Complement Alternat Med. 2011;2011:619650. doi: 10.1093/ecam/neq016. Epub 2011 Jan 9.
9
Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study.限制环氧化酶-2 抑制剂处方的监管活动对人群的影响：生态研究。
Br J Clin Pharmacol. 2009 Nov;68(5):752-64. doi: 10.1111/j.1365-2125.2009.03500.x.
10
Evaluation of inhibitory activities of plant extracts on production of LPS-stimulated pro-inflammatory mediators in J774 murine macrophages.评价植物提取物对 J774 鼠巨噬细胞产生脂多糖刺激的促炎介质的抑制活性。
Mol Cell Biochem. 2010 Mar;336(1-2):127-35. doi: 10.1007/s11010-009-0263-6. Epub 2009 Oct 8.

本文引用的文献

1
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.充血性心力衰竭患者使用塞来昔布、罗非昔布或非甾体抗炎药的疗效差异：基于人群的研究。
BMJ. 2005 Jun 11;330(7504):1370. doi: 10.1136/bmj.330.7504.1370.
2
Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.服用环氧化酶-2抑制剂或传统非甾体抗炎药患者的心肌梗死风险：基于人群的巢式病例对照分析
BMJ. 2005 Jun 11;330(7504):1366. doi: 10.1136/bmj.330.7504.1366.
3
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.心脏手术后COX-2抑制剂帕瑞昔布和伐地昔布的并发症。
N Engl J Med. 2005 Mar 17;352(11):1081-91. doi: 10.1056/NEJMoa050330. Epub 2005 Feb 15.
4
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.在一项预防结直肠腺瘤的临床试验中与塞来昔布相关的心血管风险。
N Engl J Med. 2005 Mar 17;352(11):1071-80. doi: 10.1056/NEJMoa050405. Epub 2005 Feb 15.
5
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.一项结直肠腺瘤化学预防试验中与罗非昔布相关的心血管事件。
N Engl J Med. 2005 Mar 17;352(11):1092-102. doi: 10.1056/NEJMoa050493. Epub 2005 Feb 15.
6
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.心血管事件风险与罗非昔布：累积荟萃分析
Lancet. 2004;364(9450):2021-9. doi: 10.1016/S0140-6736(04)17514-4.
7
Better reporting of harms in randomized trials: an extension of the CONSORT statement.随机试验中不良事件的更好报告：CONSORT声明的扩展
Ann Intern Med. 2004 Nov 16;141(10):781-8. doi: 10.7326/0003-4819-141-10-200411160-00009.
8
Lessons from the withdrawal of rofecoxib.罗非昔布撤市的教训。
BMJ. 2004 Oct 16;329(7471):867-8. doi: 10.1136/bmj.329.7471.867.
9
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.在治疗性关节炎研究和胃肠道事件试验（TARGET）中罗美昔布与萘普生和布洛芬的比较：心血管结局的随机对照试验
Lancet. 2004;364(9435):675-84. doi: 10.1016/S0140-6736(04)16894-3.
10
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.环氧化酶：新形式、新抑制剂及临床经验教训
FASEB J. 2004 May;18(7):790-804. doi: 10.1096/fj.03-0645rev.